Lawrence Afrin, MD, discusses the complexities of mast cell activation syndrome. Dr Afrin reviews the underlying mechanisms of mast cells, the role of mast cells in chronic illnesses, and the need for personalized treatment approaches for patients.
In this detailed webinar on systemic mastocytosis, Dr. Miti introduces Professor Prithviraj Bose, an expert in the field, who discusses the complexities of diagnosing and managing systemic mastocytosis…
In an interview conducted at the 2024 American Society of Hematology Annual Meeting in San Diego, California, Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center,…
John M. Fahrenholz, MD, Vanderbilt University Medical Center, Nashville, Tennessee, discusses questions about nonadvanced systemic mastocytosis submitted by participants. Topics include triggers for mast cell activation, management strategies…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
In an expert roundtable discussion, Matthew P. Giannetti, MD, Harvard Medical School, Brigham and Women’s Hospital Mastocytosis Center, Boston, Massachusetts; Lauren M. Madigan, MD, University of Utah, University…
